The identification of specific SNPs associated with type 2 diabetes comorbid depression paves the way for personalized medicine approaches, where SIRT1-targeted therapies might be developed to manage or mitigate the effects of this comorbidity. This evidence concerns the gene SIRT1 and type 2 diabetes mellitus.